NCT07115004View on ClinicalTrials.gov

Study to Evaluate Subcutaneous (SC) VGA039 in Patients With Von Willebrand Disease (VWD)

PHASE3RecruitingINTERVENTIONAL
Enrollment

60

Participants

Timeline

Start Date

September 1, 2025

Primary Completion Date

October 31, 2028

Study Completion Date

October 31, 2028

Conditions
Von Willebrand Disease (VWD)
Interventions
DRUG

VGA039

VGA039 SC administered for 49-weeks during the interventional phase following a 24-week observational period.

Trial Locations (1)

27560

RECRUITING

Science 37, Inc. (Virtual Clinical MetaSite), Morrisville

All Listed Sponsors
lead

Vega Therapeutics, Inc

INDUSTRY